Home English Medical Ethics and Right-to-Try Medical Ethics and Right-to-Try Share on Facebook Share on LinkedIn Share on Twitter Copy this URL Share via Email Right-to-Try is legislation that allows terminally ill patients to access investigational treatments which have passed Phase I testing through the Food and Drug Administration (FDA), but are not available yet to the public because they have not yet been approved by the FDA. In this informative webinar, Professor Bateman-House, Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center, discusses the legislation, break down the language, and explain how Right-to-Try can affect cancer patients. Watch the Webinar View the Slides Medial Ethics & Right to Try Webinar from Fight Colorectal Cancer About the Presenter Alison Bateman-House, PHD, MPH, MA Alison Bateman-House, PHD, MPH, MA, is an Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center. She has advanced training in bioethics, public health, and history, and she specializes in the ethics and history of human subjects research and the ethics and history of public health. Alison Bateman-House serves as the non-voting, nonpaid deputy chairperson of the Compassionate Use Advisory Committee (CompAC), an external, expert panel of internationally recognized medical experts, bioethicists, and patient representatives formed by NYU School of Medicine, which advises the Janssen division of Johnson and Johnson about requests for compassionate use of some of its investigational medicines. She also co-chairs the NYU School of Medicine Working Group on Compassionate Use and Pre-Approval Access. Sponsored By: